tbuckley/cabot-search huggingface dataset:
Association of Serum Ferritin Levels and Methylprednisolone Treatment With Outcomes in Nonintubated Patients With Severe COVID-19 Pneumonia
Authors: Aikaterini Papamanoli, Andreas P. Kalogeropoulos, Jessica Hotelling, Jeanwoo Yoo, Prabhjot Grewal, William Predun, Robin P. Jacob, Kerry Cao, Luis A. Marcos, Hal A. Skopicki
Journal: JAMA Network Open (2021)

Serum ferritin, an acute phase marker of inflammation, has several physiologic functions, including limiting intracellular oxidative stress. Whether the effectiveness of corticosteroids differs according to serum ferritin level in COVID-19 has not been reported.To examine the association between admission serum ferritin level and methylprednisolone treatment outcomes in nonintubated patients with severe COVID-19.This retrospective cohort study included patients with severe COVID-19 admitted to an academic referral center in Stony Brook, New York, from March 1 to April 15, 2020, receiving high-flow oxygen therapy (fraction of inspired oxygen, ≥50%). The outcomes of treatment with methylprednisolone were estimated using inverse probability of treatment weights, based on a propensity score comprised of clinical and laboratory variables. Patients were followed up for 28 days. Data were analyzed from December 19, 2020, to July 22, 2021.Systemic methylprednisolone administered per the discretion of the treating physician.The primary outcome was mortality, and the secondary outcome was a composite of death or mechanical ventilation at 28 days.Among 380 patients with available ferritin data (median [IQR] age, 60 years [49-72] years; 130 [34.2%] women; 250 [65.8%] men; 310 White patients [81.6%]; 47 Black patients [12.4%]; 23 Asian patients [6.1%]), 142 patients (37.4%) received methylprednisolone (median [IQR] daily dose, 160 [120-240] mg). Ferritin levels were similar in patients who received methylprednisolone vs those who did not (median [IQR], 992 [509-1610] ng/mL vs 893 [474-1467] ng/mL; P = .32). In weighted analyses using tertiles of ferritin values (lower: 29-619 ng/mL; middle: 623-1316 ng/mL; upper: 1322-13 418 ng/mL), methylprednisolone was associated with lower mortality in patients with ferritin in the upper tertile (HR, 0.16; 95% CI, 0.06-0.45) and higher mortality in those with ferritin in the middle (HR, 2.46; 95% CI, 1.15-5.28) and lower (HR, 2.43; 95% CI, 1.13-5.22) tertiles (P for interaction < .001). Composite end point rates were lower with methylprednisolone in patients with ferritin in the upper tertile (HR, 0.45; 95% CI, 0.25-0.80) but not in those with ferritin in the middle (HR, 0.83; 95% CI, 0.50-1.39) and lower (HR, 0.89; 95% CI, 0.51-1.55) tertiles (P for interaction = .11).In this cohort study of nonintubated patients with severe COVID-19, methylprednisolone was associated with improved clinical outcomes only among patients with admission ferritin in the upper tertile of values.
Methotrexate for pityriasis lichenoides et varioliformis acuta (Mucha-Habermann disease) and pityriasis lichenoides chronica: A retrospective case series of 33 patients with an emphasis on outcomes
Authors: Matthew L. Hrin, Nathan L. Bowers, Joseph L. Jorizzo, Steven R. Feldman, William W. Huang
Journal: Journal of the American Academy of Dermatology (2021)
Miniature-probe endoscopic ultrasonography using a rubber balloon to evaluate gastrointestinal carcinomas in poor underwater conditions
Authors: Nobuya Kobayashi, Hideki Kobara, Noriko Nishiyama, Tingting Shi, Taiga Chiyo, Tatsuo Yachida, Tsutomu Masaki
Journal: Endoscopy (2021)

Miniature-probe endoscopic ultrasonography (m-EUS) is routinely used to diagnose the invasion depth of gastrointestinal carcinomas [1] [2]. However, the efficacy of EUS is sometimes limited in locations such as the esophagus and esophagogastric junction, where water does not accumulate sustainably [3] [4]. A rubber balloon (MAJ-213; Olympus, Tokyo, Japan) is clinically available for attaching to a convex-type EUS probe [5]. We describe a novel m-EUS method using this rubber balloon without the need for intraluminal underwater conditions ([Fig. 1]; [Video 1]).
1316P Comparative effectiveness of atezolizumab (Atz) versus docetaxel (Dtx) or nivolumab (Niv) in previously treated (pt) patients with advanced non-small cell lung cancer (aNSCLC): A US real-world (RW) study
Authors: V. Subbiah, A. Gupta, J. Ray, P. Arora, K. Thorlund, S. Ramagopalan
Journal: Annals of Oncology (2021)
1571P COVID-19 positivity rates in patients with an active cancer diagnosis in the University of California Cancer Consortium
Authors: J. Hong, H.T. Borno, O. Harismendy, S. Yousefi, P. Cinar, H.S. Rugo, M-O. Kim, V.S. Koshkin, A. Bailey, R.R. McKay, E.J. Small
Journal: Annals of Oncology (2021)
1696TiP Phase Ib study to assess the effect of PF-06946860 on appetite following subcutaneous administration in patients with anorexia and advanced cancer
Authors: E.J. Roeland, S. Yennu, E. Del Fabbro, C. Buckeridge, K.M. Thayer, S.M. Collins, S.L. Lubaczewski, E.Q. Wang, R.A. Calle
Journal: Annals of Oncology (2021)
213P Predictive markers of cardiotoxicity associated with breast cancer treatment
Authors: I.C. Nogueira Costa, T. Proença, J.S. Reis, M. Carvalho, M.J. Costa, A.C. Valente, M. Paiva, C. Fernandes, N. Tavares, I. Sousa, D. Almeida, C. Caeiro, I. Augusto
Journal: Annals of Oncology (2021)
1204P Cost-benefit analysis of ALK diagnosis in patients with non-small cell lung cancer in Spain
Authors: A.L. Ortega Granados, F. Rojo Todo, R. Álvarez Álvarez, M. Majem Tarruella, L. Ruiz de Alda Iparraguirre, J.F. García Verdes-Montenegro, R. Gordo Flores, A. González-Domínguez, Y. Ivanova Markova, R. Sánchez San Cristóbal
Journal: Annals of Oncology (2021)
The <i>EGFRvIII</i> transcriptome in glioblastoma: A meta-omics analysis
Authors: Youri Hoogstrate, Santoesha A Ghisai, Maurice de Wit, Iris de Heer, Kaspar Draaisma, Job van Riet, Harmen J G van de Werken, Vincent Bours, Jan Buter, Isabelle Vanden Bempt, Marica Eoli, Enrico Franceschi, Jean-Sebastien Frenel, Thierry Gorlia, Monique C Hanse, Ann Hoeben, Melissa Kerkhof, Johan M Kros, Sieger Leenstra, Giuseppe Lombardi, Slávka Lukacova, Pierre A Robe, Juan M Sepulveda, Walter Taal, Martin Taphoorn, René M Vernhout, Annemiek M E Walenkamp, Colin Watts, Michael Weller, Filip Y F de Vos, Guido W Jenster, Martin van den Bent, Pim J French
Journal: Neuro-Oncology (2021)

EGFR is among the genes most frequently altered in glioblastoma, with exons 2-7 deletions (EGFRvIII) being among its most common genomic mutations. There are conflicting reports about its prognostic role and it remains unclear whether and how it differs in signaling compared with wildtype EGFR.To better understand the oncogenic role of EGFRvIII, we leveraged 4 large datasets into 1 large glioblastoma transcriptome dataset (n = 741) alongside 81 whole-genome samples from 2 datasets.The EGFRvIII/EGFR expression ratios differ strongly between tumors and range from 1% to 95%. Interestingly, the slope of relative EGFRvIII expression is near-linear, which argues against a more positive selection pressure than EGFR wildtype. An absence of selection pressure is also suggested by the similar survival between EGFRvIII-positive and -negative glioblastoma patients. EGFRvIII levels are inversely correlated with pan-EGFR (all wildtype and mutant variants) expression, which indicates that EGFRvIII has a higher potency in downstream pathway activation. EGFRvIII-positive glioblastomas have a lower CDK4 or MDM2 amplification incidence than EGFRvIII-negative (P = .007), which may point toward crosstalk between these pathways. EGFRvIII-expressing tumors have an upregulation of "classical" subtype genes compared to those with EGFR-amplification only (P = 3.873e-6). Genomic breakpoints of the EGFRvIII deletions have a preference toward the 3'-end of the large intron-1. These preferred breakpoints preserve a cryptic exon resulting in a novel EGFRvIII variant and preserve an intronic enhancer.These data provide deeper insights into the complex EGFRvIII biology and provide new insights for targeting EGFRvIII mutated tumors.
1125P Analytical assessment of a diagnostic immunohistochemical assay for the detection of folate receptor-ɑ in epithelial ovarian cancers
Authors: R. James, B. Admire, T. Sisserson, Z. Cai, M. Dumas, L.J. Inge, J. Baumann, P. Towne, D. Dalvi, E.A. ElGabry
Journal: Annals of Oncology (2021)
1358P Phase I dose-escalation study to evaluate safety and clinical activity of c-MET inhibitor ABN401 in patients with advanced solid tumor
Authors: D.H. Lee, A. Roohullah, B.C. Cho, C. Lemech, P. de Souza, M. Millward, J. Choi, K.E. Park, M. Lee, Y. Kim, S. Park, J. Lee, J. Kim, Y.K. Shin, J-Y. Han
Journal: Annals of Oncology (2021)
1096O Lanreotide autogel/depot (LAN) in patients with advanced bronchopulmonary (BP) neuroendocrine tumors (NETs): Results from the phase III SPINET study
Authors: E. Baudin, D. Horsch, S. Singh, M.E. Caplin, D. Ferone, E.M. Wolin, J. Capdevila, W.A. Buikhuisen, M. Raderer, E. Dansin, C. Grohe, A. Houchard, X-M. Truong Thanh, D. Reidy-Lagunes
Journal: Annals of Oncology (2021)
Carbon‐Based Materials for Articular Tissue Engineering: From Innovative Scaffolding Materials toward Engineered Living Carbon
Authors: Monsur Islam, Andrés Díaz Lantada, Dario Mager, Jan G. Korvink
Journal: Advanced Healthcare Materials (2021)

Carbon materials constitute a growing family of high-performance materials immersed in ongoing scientific technological revolutions. Their biochemical properties are interesting for a wide set of healthcare applications and their biomechanical performance, which can be modulated to mimic most human tissues, make them remarkable candidates for tissue repair and regeneration, especially for articular problems and osteochondral defects involving diverse tissues with very different morphologies and properties. However, more systematic approaches to the engineering design of carbon-based cell niches and scaffolds are needed and relevant challenges should still be overcome through extensive and collaborative research. In consequence, this study presents a comprehensive description of carbon materials and an explanation of their benefits for regenerative medicine, focusing on their rising impact in the area of osteochondral and articular repair and regeneration. Once the state-of-the-art is illustrated, innovative design and fabrication strategies for artificially recreating the cellular microenvironment within complex articular structures are discussed. Together with these modern design and fabrication approaches, current challenges, and research trends for reaching patients and creating social and economic impacts are examined. In a closing perspective, the engineering of living carbon materials is also presented for the first time and the related fundamental breakthroughs ahead are clarified.
1098O Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)
Authors: M.C. Riesco-Martinez, J. Capdevila, V. Alonso, P. Jimenez-Fonseca, A. Teule, E. Grande, I. Sevilla, M. Benavent Viñuales, T. Alonso-Gordoa, A. Custodio, J. Hernando, E. Polo, O.A. Castillo Trujillo, R. Garcia-Carbonero
Journal: Annals of Oncology (2021)
1377P Preliminary efficacy and safety results of KN026 (a HER2-targeted bispecific antibody) in combination with KN046 (an anti-PD-L1/CTLA-4 bispecific antibody) in patients (pts) with HER2-positive gastrointestinal tumors
Authors: J. Gong, L. Shen, S. Luo, Z. Dong, D. Liu, S. An, J. Xu, J. Yang, Y. Qi, J. Men, L. Kong, Y. Yang, T. Xu
Journal: Annals of Oncology (2021)
577O PRINCE: Interim analysis of the phase Ib study of 177Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
Authors: S.K. Sandhu, A.M. Joshua, L. Emmett, L. Spain, L.G. Horvath, M. Crumbaker, A. Anton, R. Wallace, A. Pasam, M. Bressel, E. Cassidy, P. Banks, A.R. Kumar, R. Alipour, T. Akhurst, G. Kong, I.D. Davis, S. Williams, R. Hicks, M. Hofman
Journal: Annals of Oncology (2021)
1012P Intratumoral immunotherapy with a novel TLR1/2/3 agonist, L-pampo, induces robust anti-tumor immune responses and enhances immune checkpoint blockade
Authors: W.S. Lee, D.S. Kim, S.J. Lee, Y.E. Kim, Y.K. Heo, B.C. Ahn, H.G. Kang, J.K. Cho, J.S. Yum, C. Kim, H.J. Chon
Journal: Annals of Oncology (2021)
1280P Sitravatinib + tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)
Authors: Q. Zhou, X. Yu, B. Gao, Z. Ma, Q. Chu, D. Huang, J. Zhao, D. Day, A.L. Body, H. Pan, J. Cui, C. Chen, X. Xiang, C. Fei, L. Yang, Y-L. Wu
Journal: Annals of Oncology (2021)
Molecular insights into AabZIP1-mediated regulation on artemisinin biosynthesis and drought tolerance in Artemisia annua
Authors: Guoping Shu, Yueli Tang, Mingyuan Yuan, Ning Wei, Fangyuan Zhang, Chunxian Yang, Xiaozhong Lan, Min Chen, Kexuan Tang, Lien Xiang, Zhihua Liao
Journal: Acta Pharmaceutica Sinica B (2021)

Artemisia annua is the main natural source of artemisinin production. In A. annua, extended drought stress severely reduces its biomass and artemisinin production while short-term water-withholding or abscisic acid (ABA) treatment can increase artemisinin biosynthesis. ABA-responsive transcription factor AabZIP1 and JA signaling AaMYC2 have been shown in separate studies to promote artemisinin production by targeting several artemisinin biosynthesis genes. Here, we found AabZIP1 promote the expression of multiple artemisinin biosynthesis genes including AaDBR2 and AaALDH1, which AabZIP1 does not directly activate. Subsequently, it was found that AabZIP1 up-regulates AaMYC2 expression through direct binding to its promoter, and that AaMYC2 binds to the promoter of AaALDH1 to activate its transcription. In addition, AabZIP1 directly transactivates wax biosynthesis genes AaCER1 and AaCYP86A1. The biosynthesis of artemisinin and cuticular wax and the tolerance of drought stress were significantly increased by AabZIP1 overexpression, whereas they were significantly decreased in RNAi-AabZIP1 plants. Collectively, we have uncovered the AabZIP1-AaMYC2 transcriptional module as a point of cross-talk between ABA and JA signaling in artemisinin biosynthesis, which may have general implications. We have also identified AabZIP1 as a promising candidate gene for the development of A. annua plants with high artemisinin content and drought tolerance in metabolic engineering breeding.
Palliative care of patients with haematological malignancies: strategies to overcome difficulties via integrated care
Authors: Ulrich Wedding
Journal: The Lancet Healthy Longevity (2021)

Palliative care, hospice care, and end of life care have been the focus of increased attention over the past two decades; palliative care has shifted from being introduced only at the end of life to becoming an integrated part of routine care for patients. Currently, the timing and extent of the integration of palliative care into standard medical care practice depends on the underlying disease. Patients with haematological malignancies receive less palliative care initiated at a later disease stage compared with patients with other types of cancer. All patients in need of palliative care, hospice care, and end of life care should be given the chance to benefit from these types of care. Patients, their relatives, health-care professionals, and the health-care system can all benefit from the closer integration of palliative, hospice, and end of life care, even in combination with disease orientated treatment. Important factors to consider when introducing palliative care for patients with haematological malignancies are the different treatment strategies for each disease, the heterogeneous dynamics of the different haematological malignancies, the broad variance of therapeutic effects, and patients' dependence on the health-care system for the administration of transfusions and antimicrobial treatment, which is different from patients with solid tumours. Key areas that physicians should pay particular attention to are strategies for communication with patients to aid their understanding of their illness and prognosis and concepts to address special needs of patients with haematological malignancies (eg, transfusion requirements and symptom control). Because haematological malignancies mainly affect patients in advanced age, this Series paper integrates a special focus on age-associated topics.
A MYT1L syndrome mouse model recapitulates patient phenotypes and reveals altered brain development due to disrupted neuronal maturation
Authors: Jiayang Chen, Mary E. Lambo, Xia Ge, Joshua T. Dearborn, Yating Liu, Katherine B. McCullough, Raylynn G. Swift, Dora R. Tabachnick, Lucy Tian, Kevin Noguchi, Joel R. Garbow, John N. Constantino, Harrison W. Gabel, Keith B. Hengen, Susan E. Maloney, Joseph D. Dougherty
Journal: Neuron (2021)
Cultural adaptation: a framework for addressing an often-overlooked dimension of digital health accessibility
Authors: Jayson S. Marwaha, Joseph C. Kvedar
Journal: npj Digital Medicine (2021)

Abstract Relatively little is known about how to make digital health tools accessible to different populations from a cultural standpoint. Alignment with cultural values and communication styles may affect these tools’ ability to diagnose and treat various conditions. In this Editorial, we highlight the findings of recent work to make digital tools for mental health more culturally accessible, and propose ways to advance this area of study.
Use of Second-line Immunotherapy in Control Arms of Randomized Clinical Trials in Kidney Cancer
Authors: John Sharp, Ali Raza Khaki, Vinay Prasad
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Immunotherapy (anti–programmed death ligand 1 antibodies) is associated with improved survival rates in advanced kidney cell carcinoma (KCC) after progression on first-line tyrosine kinase inhibitor (TKI) treatment. It is unknown whether and to what degree patients in the control arm receive postprotocol immunotherapy in trials comparing combination immunotherapy regimens with TKI in first-line advanced KCC. <h3>Objective</h3> To characterize the proportion of patients in the control arm who received postprotocol immunotherapy in trials comparing combination immunotherapy regimens with TKI in first-line advanced KCC. <h3>Evidence Review</h3> A search of PubMed was conducted to identify randomized clinical trials of combination immunotherapy compared with TKI in first-line advanced KCC between January 1, 2015, and February 28, 2021. Combination immunotherapy was defined as an anti–programmed death ligand 1 agent and an additional agent. Search terms included<i>renal cell cancer</i>and<i>first-line</i>and were filtered by the type<i>clinical trial</i>. All English-language trials of combination immunotherapy compared with a TKI were included. The trials and their protocols and supplements were analyzed to determine the proportion of patients in the control arm receiving postprotocol immunotherapy. <h3>Findings</h3> A total of 106 articles met search criteria and were screened. A total of 6 trials and 3 published updates of trial results were included in the systematic review. Of 2565 patients assigned to control arm groups, 2069 (81%) were no longer on TKI at last data cutoff. Of patients in the control arm who discontinued TKI, 932 (45%) received postprotocol immunotherapy. Of patients in the control arm receiving any type of postprotocol therapy, 66.4% received immunotherapy. <h3>Conclusions and Relevance</h3> This systematic review found that the proportion of patients in the control arm receiving postprotocol immunotherapy is low in randomized clinical trials of first-line combination immunotherapy regimens for advanced KCC. Appropriate use of postprotocol therapy is essential to answering the question of whether a combination or sequential treatment strategy with immunotherapy is superior.
LBA59 LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study
Authors: P. Pautier, A. Italiano, S. Piperno-Neumann, C.M. Chevreau, N. Penel, D. Cupissol, P. Boudou Rouquette, F. Bertucci, C. Balleyguier, V. Lebrun-Ly, J-Y. Blay, E. Kalbacher, C. Delcambre, E. Bompas, O. Collard, N. Isambert, C. Guillemet, M. Rios, M. Sundqvist, F. Duffaud
Journal: Annals of Oncology (2021)
1617P Sustained cancer clinical trial activity during the COVID-19 pandemic
Authors: A. Bayle, C. Baldini, P. Martin Romano, J-M. Michot, S. Champiat, R. Bahleda, A. Gazzah, A. Marabelle, L. Verlingue, A. Geraud, D. Morel, S. Michiels, V. Ribrag, A. Hollebecque, L. Albiges, B. Besse, J-C. Soria, C. Massard, F. Barlesi, S. Postel-Vinay
Journal: Annals of Oncology (2021)
Covid-19: Vaccine advisory committee must be more transparent about decisions, say researchers
Authors: Elisabeth Mahase
Journal: BMJ (2021)

The government has refused to release the minutes of the meeting in which its vaccine advisory committee decided not to recommend vaccinating all 12-15 year olds against covid-19.1

The UK Health Security Agency, which replaced Public Health England, rejected a freedom of information request for the document on the grounds that it intended to publish the minutes “in due course.”

The agency argued that it was in the public interest to withhold the information until it could be released in a “simultaneous, coordinated manner” and that disclosing …
Allergens in patients with a diagnosis of seborrheic dermatitis, North American Contact Dermatitis Group data, 2001-2016
Authors: Jonathan I. Silverberg, Alexander Hou, Erin M. Warshaw, Howard I. Maibach, Donald V. Belsito, Joel G. DeKoven, Kathryn A. Zug, James S. Taylor, Denis Sasseville, Anthony F. Fransway, Vincent A. DeLeo, Melanie D. Pratt, Margo J. Reeder, Amber R. Atwater, Joseph F. Fowler, Matthew J. Zirwas, James G. Marks, Cory A. Dunnick, Marie-Claude Houle
Journal: Journal of the American Academy of Dermatology (2021)
Dengue and Zika virus infections in children elicit cross-reactive protective and enhancing antibodies that persist long term
Authors: Leah C. Katzelnick, Jose Victor Zambrana, Douglas Elizondo, Damaris Collado, Nadezna Garcia, Sonia Arguello, Juan Carlos Mercado, Tatiana Miranda, Oscarlett Ampie, Brenda Lopez Mercado, César Narvaez, Lionel Gresh, Raquel A. Binder, Sergio Ojeda, Nery Sanchez, Miguel Plazaola, Krista Latta, Amy Schiller, Josefina Coloma, Fausto Bustos Carrillo, Federico Narvaez, M. Elizabeth Halloran, Aubree Gordon, Guillermina Kuan, Angel Balmaseda, Eva Harris
Journal: Science Translational Medicine (2021)

Unexpectedly, cross-reactive antibodies are stable or rise after primary dengue and Zika virus infection and wane slowly after secondary infection.
502P Impact of different selection approaches for identifying Lynch syndrome-related colorectal cancer patients
Authors: D. Fanale, A. Dimino, C. Filorizzo, C. Brando, L. Incorvaia, L. Magrin, R. Sciacchitano, L.R. Corsini, A. Fiorino, N. Barraco, None M. bono, V. Calò, D. Cancelliere, A. Cucinella, G. Madonia, E. Pedone, A. Pivetti, R. Scalia, A. Russo, V. Bazan
Journal: Annals of Oncology (2021)
48P (BREGO) Regorafenib combined with modified m-GEMOX in patients with advanced biliary tract cancer (BTC): A phase II randomized trial
Authors: E. Assenat, J.F. Blanc, M. Bouattour, L. Gauthier, Y. Touchefeu, F. Portales, C. Borg, N. Fares, L. Mineur, J-P. Bleuse, T. Mazard
Journal: Annals of Oncology (2021)
175P Prosigna test for early breast cancer patients in real-life
Authors: D. Hequet, R. Rouzier, F. Lerebours, E. Menet, F. Dalenc, V. Nicolai, N. Hajjaji, S. Lavau-Denes, V. Fermeaux, L. Texier, A. Cayre, E. Charafe Jauffret, A. Boucrauta, O. Tredan, J. Lopez
Journal: Annals of Oncology (2021)